NCT06663618 Short-term Glucocorticoid Combined with MMF for IgG4-RD
| NCT ID | NCT06663618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wen Zhang |
| Condition | IgG4-related Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 63 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2025-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 63 participants in total. It began in 2023-09-01 with a primary completion date of 2025-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease
Eligibility Criteria
Inclusion Criteria: 1. 18-80 years old; 2. All patients must meet the comprehensive diagnostic criteria of IgG4-RD revised in Japan in 2020 or the classification criteria of IgG4-RD formulated by ACR/EULAR in 2019; 3. Active IgG4-RD (at least one organ has an IgG4-RD reaction score \>=2 at the time of enrollment.)； 4. No previous medication or recurrence after withdrawal. Exclusion Criteria: 1. Combined with other autoimmune diseases as the main diagnosis. 2. Pregnant or lactating women 3. Patients with malignant tumor 4. Active bacterial, fungal, viral or mycobacterial infections. 5. Severe complications of important organs, and the expected survival time is less than 6 months.
Contact & Investigator
Wen Zhang, MD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06663618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying IgG4-related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06663618 currently recruiting?
Yes, NCT06663618 is actively recruiting participants. Contact the research team at drpenglinyi@163.com for enrollment information.
Where is the NCT06663618 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06663618 clinical trial?
NCT06663618 is sponsored by Wen Zhang. The principal investigator is Wen Zhang, MD at Peking Union Medical College Hospital. The trial plans to enroll 63 participants.